Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  PULMONARY DRUG DELIVERY TECHNOLOGIES
A Global Strategic Business Report

This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in Millions of US$. The specific product segments analyzed are Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Nebulizers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 55 companies including many key and niche players worldwide such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes Inc., Aradigm Corporation, AstraZeneca Plc, Baxter Healthcare Corporation, Chiesi Farmaceutici SpA, Consort Medical Plc, Dey L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, Nektar Therapeutics, Oriel Therapeutics Inc., Sepracor Inc., SkyePharma Plc, and Vectura Group Plc . Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1244  PAGES:    301
PRICE:    $3950  DATE:       May 2008
COMPANIES:  55  MARKET DATA TABLES:   102
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  PULMONARY DRUG DELIVERY TECHNOLOGIES (Complete Report) Pages : 301   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Metered Dose Inhalers (MDIs).....I-3
Dry Powder Inhalers (DPIs).....I-3
  
   Nebulizers.....I-4  
II. EXECUTIVE SUMMARY80$2250
  1. Market Dynamics.....II-15 $500  
   Market Overview.....II-1
Pulmonary Devices: Gaining Pace.....II-1
Market Highlights.....II-1
1$100
   Primary Position of the U.S.....II-2
Pulmonary Drug Delivery: An Attractive Non-Invasive Option.....II-2
1$100
   Chief Pulmonary Delivery Technologies.....II-3
Most Effective Route for Respiratory Syndromes.....II-3
1$100
   Leading Inhalation Prescription Drugs Across All Segments.....II-4
The Attractiveness of Inhalers.....II-4
Choice of Drug Delivery System.....II-4
Inhalation Therapy: A Retrospection.....II-4
1$100
   Pulmonary Drug Delivery - Market Snapshots.....II-5
1$100
  2. Trends and Issues.....II-65 $500  
   Market Snippets.....II-6
Focus of New Age Pulmonary Devices.....II-6
Dry Powder Inhalation: A Promising Technology.....II-6
1$100
   Research Activities in Inhaled Drug Delivery.....II-7
Lung Versus Oropharyngeal Deposition: A Major Challenge.....II-7
Competitive Environment .....II-7
A Backdrop.....II-7
1$100
   Market Leaders.....II-8
Table 1: World Market for Inhaled Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Flovent, Serevent, Pulmicort, Atrovent, Ventolin, and Others (includes corresponding Graph/Chart).....II-8
Industry Efforts.....II-8
1$300
   Inefficient Use of Pulmonary Drug Delivery Systems.....II-9
MDIs.....II-9
Spacers.....II-9
1$100
   Dry Powder Inhalers.....II-10
Issues Facing Various Inhalation Devices.....II-10
Jet Nebulizers.....II-10
MDIs .....II-10
DPIs.....II-10
1$100
  3. Growth Drivers.....II-113 $300  
   Growth Drivers in Pulmonary Drug Delivery.....II-11
Use of Nano Technology in Drug Delivery Products.....II-11
Other Growth Areas.....II-11
Table 2: World Market for Pulmonary Drug Delivery Technologies (2000 & 2005): Percentage Share Breakdown of Sales by Drug Category- Bronchodilators, Anti-Inflammatories, Protein/Peptide Therapeutics, Combination, and Other Small Molecule (includes corresponding Graph/Chart).....II-11
1$300
   Innovative Pulmonary Devices Shape Progress.....II-12
Pulmonary Insulin.....II-12
Alternative Drug Delivery Systems: A Review.....II-12
Market Size.....II-12
1$100
   Inhaled Small Molecule Therapeutics.....II-13
1$100
  4. Product Overview.....II-1419 $1200  
   Definition of Pulmonary Drug Delivery System.....II-14
Pulmonary Drug Delivery Technologies: An Introduction.....II-14
An Overview of Key Features of Popular Inhalation Devices.....II-14
1$100
   Product Segments.....II-15
A. Nebulizers.....II-15
Nebulizers: Key Devices for Bronchodilator Delivery.....II-15
1$100
   Working Principle of a Nebulizer.....II-16
Use of UDMs in Nebulizers.....II-16
Types of Nebulizers.....II-16
Ultrasonic Nebulizers.....II-16
1$100
   Device Components.....II-17
Gray Areas .....II-17
1$100
   Benefits.....II-18
Limitations.....II-18
Pneumatic Nebulizers.....II-18
Breath-Actuated Nebulizers.....II-18
Continuous Nebulization.....II-18
1$100
   Nebulizers for Specific Applications.....II-19
Active Venturi Nebulizers.....II-19
New Designs for Improved Nebulizer Performance.....II-19
Limitations of Nebulizers.....II-19
1$100
   Nebulizers and MDIs.....II-20
B. Metered Dose Inhalers (MDIs).....II-20
Working Principle of an MDI.....II-20
1$100
   MDI Timeline.....II-211$100
   CFC-Propellant based MDIs.....II-22
Ban on CFCs.....II-22
Use of Spacers in MDIs.....II-22
Benefits of Spacers.....II-22
1$100
   Types of Spacers.....II-23
Issue of Electrostatic Charge in Spacers.....II-23
Suitability of Spacers.....II-23
1$100
   Innovative Delivery Systems.....II-24
Cutting Edge Developments in MDIs.....II-24
Merits of pMDIs.....II-24
Limitations.....II-24
1$100
   Issues MDIs.....II-25
MDIs & Future.....II-25
Supply of MDIs in Developing Nations.....II-25
C. Dry Powder Inhalers (DPIs).....II-25
1$100
   Inspiratory Flow Rate in DPIs.....II-26
DPIs to Create Significant Impact.....II-26
DPIs: Not Entirely a New Concept.....II-26
Working Principle of DPIs.....II-26
1$100
   Deaggregation in Dry Powder Inhalers (DPIs).....II-27
Types of DPIs.....II-27
Passive DPI.....II-27
Active DPI.....II-27
Single-dose DPIs.....II-27
Multi-dose DPIs.....II-27
1$100
   Other Types.....II-28
Development Activities in DPI.....II-28
Cost Considerations.....II-28
Benefits of DPI.....II-28
1$100
   Limitations.....II-29
Issues.....II-29
In a nutshell.....II-29
Suitability of DPIs.....II-29
Trends.....II-29
1$100
   Growth Areas.....II-30
Comparison between MDI and DPI.....II-30
1$100
   Other Types of Inhalers.....II-31
Single-Breath Liquid Based Systems.....II-31
Multi Drug Atomizers.....II-31
Liquid Sieving.....II-31
1$100
   Unit Dose Single Breath Atomizer.....II-32
Side Effects of Inhalers.....II-32
Side Effects in Children.....II-32
1$100
  5. An Overview of Pulmonary Conditions and Therapies.....II-3311 $700  
   Drug Delivery to the Lung: An Insight.....II-33
The Respiratory System.....II-33
Methods of Drug Delivery through Pulmonary Route.....II-33
1$100
   Aerosols Systems.....II-34
Intratracheal instillation.....II-34
Insufflation.....II-34
Pulmonary Delivery Approaches.....II-34
1$100
   Controlled Release.....II-35
Asthma and COPD.....II-35
Asthma: Primary Respiratory Syndrome.....II-35
1$100
   Trigger Factors.....II-36
Magnitude of Disease.....II-36
Chronic Obstructive Pulmonary Disease.....II-36
1$100
   Magnitude of Disease.....II-37
Treatment of Asthma and COPD.....II-37
Drug Medications for Treating Asthma and COPD.....II-37
Bronchodilators (Acute Reliever Drugs).....II-37
Categories of Bronchodilators.....II-37
Beta-agonists.....II-37
Short acting beta-agonists.....II-37
1$100
   Long acting beta-agonists.....II-38
Anti-cholinergics.....II-38
Methylxanthines.....II-38
Anti-Inflammatory Medication (Controllers or Preventers).....II-38
1$100
   Inhaled glucocorticosteroids (or inhaled steroids).....II-39
Cromoglycate-like drugs.....II-39
Other Delivery Routes for Asthma and COPD Treatment.....II-39
Oral Route.....II-39
1$100
   New Oral Therapies.....II-40
Injectable Option.....II-40
Significance of Relievers and Preventers.....II-40
Steroid MDIs and DPIs.....II-40
1$100
   Benefits of Pulmonary Drug Delivery Systems.....II-41
Protein Absorption.....II-41
Convenience.....II-41
Bioavailability.....II-41
Applications of Pulmonary Technology.....II-41
Titration by Therapy.....II-41
1$100
   Titration by Patient.....II-42
Dose Reproducibility.....II-42
High Bioavailability.....II-42
Types of Inhaler Devices.....II-42
Aerosol Inhalers.....II-42
Breath-Actuated Inhalers.....II-42
1$100
   Factors Influencing Clinical Effectiveness of Inhalation Device.....II-43
Device Factors.....II-43
Patient Factors.....II-43
Drug Factors.....II-43
1$100
  6. Regulatory Environment.....II-445 $500  
   The Montreal Protocol.....II-44
FDA Bans the Use of CFC’s in Metered Dose Inhalers.....II-44
A Brief Overview of CFC-MDI Transition.....II-44
1$100
   Freon Compounds.....II-45
HFC Emissions.....II-45
1$100
   Table 3: Ozone Depletion and Global Warming Impact of Various Propellants.....II-46
Reformulation of MDIs.....II-46
Suitable Non-CFCs.....II-46
Country-wise Variations in CFC Transition.....II-46
Preference for HFCs.....II-46
Issues in HFC Use.....II-46
1$300
   HFC MDI Gaining Momentum.....II-47
HFC MDIs Commercialization.....II-47
1$100
   Potential of HFC 227ea.....II-48
1$100
  7. Product Developments.....II-493 $300  
   Generex Biotechnology Corporation Receives Patent from Mexican Institute of Industrial
  Property.....II-49
Spiriva® Ensures Relief to COPD Sufferers.....II-49
Alkermes and Eli Lilly Initiates Phase 3 Clinical Study on AIR® .....II-49
1$100
   Sepracor Receives FDA Approval for Arformoterol Tartrate Inhalation Solution.....II-50
Vectura Group Completes Phase-II Proof-of-Concept Study on VR040.....II-50
Ventaira Conducts Pharmacokinetic Study on Fluticasone Propionate.....II-50
Exubera® Inhalation Powder Receives FDA and European Commission Approval.....II-50
1$100
   LAB International Completes Phase I Trial on LAB CGRP .....II-51
Xopenex HFA Receives FDA Approval.....II-51
1$100
  8. Product Innovations/Introductions.....II-522 $200  
   Consort Medical Releases Meter Dose Inhalers .....II-52
Trinity Chiesi Pharmaceuticals Introduces Fostair.....II-52
AstraZeneca Launches Symbicort® .....II-52
Dey, L.P Unveils Perforomist™.....II-52
1$100
   Next Safety Rolls Out Hi-Performance Drug Delivery Technology.....II-53
Bang & Olufsen Medicom Unveils Aspira™.....II-53
Exaeris Launches MD Turbo™.....II-53
Chiesi Farmaceutici Launches Clenil® Modulite® pMDI.....II-53
GlaxoSmithKline Develops a New Advair Drug Formulation.....II-53
1$100
  9. Recent Industry Activity.....II-549 $600  
   Sepracor Signs Agreement with Nycomed.....II-54
Kamada Enter into Strategic Pacts with Pari Pharma.....II-54
GlaxoSmithKline Ties-Up with Amira Pharmaceuticals.....II-54
BattellePharma Takes Over Ventaira Pharmaceuticals.....II-54
Eurand Takes Over SourceCF.....II-54
1$100
   Aradigm Signs Agreement with Lung Rx for Developing AERx Essence(R) Technology
  .....II-55
Vectura Inks Agreement with a European Company.....II-55
ZYFLO CR™ Obtains FDA Clearance.....II-55
1$100
   SkyePharma Revises Agreement with Abott.....II-56
Alnylam Presents Scientific Progress of ALN-RSV01 .....II-56
Bayer HealthCare and Nektar Therapeutics to Develop NKTR- 061.....II-56
Graceway Snaps Up 3M Pharmaceuticals.....II-56
1$100
   Ventaira Pharmaceuticals Signs Agreement with Nypro .....II-57
Novartis Forms Strategic Alliance with Schering-Plough.....II-57
Aradigm Divests Intraject Subcutaneous Delivery Technology to Zogenix.....II-57
Exaeris Inks Agreement with Teamm Pharmaceuticals.....II-57
XstalBio Signs License Agreement with Boehringer Ingelheim.....II-57
1$100
   Alkermes Signs Agreement with Eli Lilly.....II-58
Vectura Signs Agreement with Boehringer Ingelheim to Develop New Dry Powder Inhaler
  .....II-58
Vectura Signs Collaboration Agreement for Combination Asthma Therapy.....II-58
Lab Pharma and Teikoku Seiyaku Sign Licensing Agreement .....II-58
1$100
   Airpharma Enters into an Agreement with Bespak for Developing Inhalation
  Device.....II-59
Eiffel Technologies Signs Agreement with MAP Pharmaceuticals.....II-59
Inyx Acquires Celltech Manufacturing Services Limited.....II-59
Nektar Therapeutics Acquires Aerogen, Inc.....II-59
1$100
   Chiesi Farmaceutici S.p.A. Enters into a Pact with NovartisPharma AG for Formoterol
  Modulite® HFA.....II-60
Respirics Receives 510(k) Clearance for MD Turbo(TM) Device.....II-60
Sanofi-Synthelabo Acquires Aventis.....II-60
SkyePharma Plc Enters into a Strategic Alliance with Vectura.....II-60
1$100
   Bespak Plc Enters into an Agreement with Innovata Biomed.....II-61
Chiesi Enters into an Agreement with Trudell Medical International.....II-61
SkyePharma Plc and AstraZeneca Announce Completion of Phase III Trials of HFA-MDI
  Corticosteroid.....II-61
Medical Industries Pens Agreement with ALR Technologies.....II-61
1$100
   Inyx Inc Forays into Dry Powder Inhalers Segment.....II-62
BattellePharma Renamed Ventaira.....II-62
Valois Purchases Rights to New Dry Powder Inhaler.....II-62
1$100
  10. Focus on Select Players.....II-636 $400  
   3M Drug Delivery Systems Division (USA).....II-63
Akela Pharma Inc. (Canada).....II-63
Alkermes Inc., (USA).....II-63
1$100
   Aradigm Corporation (USA).....II-64
AstraZeneca Plc (UK).....II-64
Baxter Healthcare Corporation (USA).....II-64
1$100
   Chiesi Farmaceutici SpA (Italy).....II-65
Consort Medical Plc (UK).....II-65
1$100
   Dey L.P. (USA).....II-66
GlaxoSmithKline Plc (UK).....II-66
1$100
   Graceway Pharmaceuticals, LLC (USA).....II-67
Nektar Therapeutics (USA).....II-67
Oriel Therapeutics Inc. (USA).....II-67
1$100
   Sepracor Inc. (USA).....II-68
SkyePharma Plc (UK).....II-68
Vectura Group Plc (UK).....II-68
1$100
  11. Global Market Perspective.....II-69   
   Table 4: World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-691$300
   Table 5: World Long-term Projections for Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-701$300
   Table 6: World 10-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart).....II-711$300
   Table 7: World Recent Past, Current and Future Analysis for Metered Dose Inhalers (MDIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-721$300
   Table 8: World Long-term Projections for Metered Dose Inhalers (MDIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-731$300
   Table 9: World 10-Year Perspective for Metered Dose Inhalers (MDIs) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart).....II-741$300
   Table 10: World Recent Past, Current and Future Analysis for Dry Powder Inhalers (DPIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-751$300
   Table 11: World Long-term Projections for Dry Powder Inhalers (DPIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-761$300
   Table 12: World 10-Year Perspective for Dry Powder Inhalers (DPIs) by Geographic Region – PercentageBreakdown of Dollar Sales for US, Canada, Japan, Europe,Asia Pacific (excluding Japan), Latin America andRest of the World Markets for Years 2003, 2008,and2012 (includes corresponding Graph/Chart).....II-771$300
   Table 13: World Recent Past, Current and Future Analysisfor Nebulizers by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-781$300
   Table 14: World Long-term Projections for Nebulizers by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-791$300
   Table 15: World 10-Year Perspective for Nebulizers by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart).....II-801$300
III. MARKET65$1950
  1. The United States.....III-115 $1075  
   A. Market Analysis.....III-1
Outlook.....III-1
Forecast for the Near Future.....III-1
1$75
   Nebulizers: Engraving High Market Interests.....III-2
Table 16: US Market for Pulmonary Drug Delivery Technologies (2000, 2005 & 2010): Percentage Share Breakdown by Application Area - Asthma/COPD, Diabetes, Cancer, Cystic Fibrosis, and Migraine (includes corresponding Graph/Chart).....III-2
New Age Pulmonary Drug Delivery Technologies.....III-2
1$150
   Inhaled Prescription Drugs in the US: Ranking of Flovent (fluticasone), Serevent
  (salmeterol), Pulmicort Turbohaler (budesonide), Atrovent (ipratropium
    bromide), Ventolin (albuterol), Combivent (ipratropium bromide + albuterol
      sulfate), and Advair/Seretide (fluticasone + salmeterol).....III-3
Role of FDA.....III-3
Metered Dose Inhalers.....III-3
Non-CFC Metered Dose Inhalers.....III-3
Table 17: U.S Market for Non-CFC Metered Dose Inhalers (2000, 2005 & 2010): Percentage Share Breakdown by Application Areas- Asthma/ COPD and Cancer.....III-3
1$150
   Table 18: Primary Manufacturers of Non-CFC Metered Dose Inhalers in the U.S (2004): Percentage Share Breakdown by 3M Drug Delivery Systems and GlaxoSmithKline.....III-4
Dry Powder Inhalers.....III-4
Table 19: US Market for Dry Powder Inhalers (2004): Percentage Share Breakdown of Value Sales by Major Players-GlaxoSmithKline, AstraZeneca and Novartis/ Schering- Plough (includes corresponding Graph/Chart).....III-4
Popular DPIs in the U.S.....III-4
1$150
   Trends in DPI Devices.....III-5
Table 20: US Market for Dry Powder Inhalers (2000, 2005, & 2010): Percentage Share Breakdown by Application Areas- Asthma/COPD, Diabetes, Cystic Fibrosis, Cancer, and Migraine (includes corresponding Graph/Chart).....III-5
Drug Delivery Market in the U.S.....III-5
1$150
   Competitive Landscape.....III-6
Product Launches/Developments.....III-6
1$75
   Strategic Corporate Developments.....III-74$300
   Select Players.....III-113$225
   B. Market Analytics.....III-14
Table 21: US Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-14
1$150
   Table 22: US Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-15

Table 23: US 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-15
1$150
  2. Canada.....III-163 $275
   A. Market Analysis.....III-16
Outlook.....III-16
Akela Pharma Inc. – A Major Player.....III-16
1$75
   B. Market Analytics.....III-17
Table 24: Canadian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-17

Table 25: Canadian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-17
1$150
   Table 26: Canadian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-18
1$150
  3. Japan.....III-194 $375  
   A. Market Analysis.....III-19
Outlook.....III-19
Market Overview.....III-19
Table 27: Japanese Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Leading Brands-Atrovent, Beclovent, Ventolin, Serevent, Pulmicort, Flonase, and Others (includes corresponding Graph/Chart).....III-19
Market Highlights.....III-19
1$150
   Strategic Corporate Developments.....III-20
Omron Healthcare Co. Ltd – A Major Player.....III-20
1$75
   B. Market Analytics.....III-21
Table 28: Japanese Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-21

Table 29: Japanese Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-21
1$150
   Table 30: Japanese 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-22
1$150
  4. Europe.....III-237 $625  
   A. Market Analysis.....III-23
Outlook.....III-23
Transition to Non-CFC MDIs.....III-23
Potential Hurdles in DPI Penetration in Europe.....III-23
1$75
   Market Awareness.....III-24
Price Issues.....III-24
Healthcare Effects.....III-24
Patient Retraining.....III-24
Strategic Corporate Development.....III-24
1$75
   B. Market Analytics.....III-25
Table 31: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-25
1$150
   Table 32: European Long-term Projections for Pulmonary Drug Delivery Technologies by Geographic Region – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-261$150
   Table 33: European 10-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-271$150
   Table 34: European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-281$150
   Table 35: European Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-29

Table 36: European 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-29
1$150
  4a. France.....III-303 $225  
   A. Market Analysis.....III-30
Outlook.....III-30
Market Overview.....III-30
Strategic Corporate Developments.....III-30
1$75
   B. Market Analytics.....III-31
Table 37: French Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-31

Table 38: French Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-31
1$150
   Table 39: French 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-32
1$150
  4b. Germany.....III-332 $175  
   Market Analysis.....III-33
Table 40: German Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-33
1$150
   Table 41: German Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-34

Table 42: German 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-34
1$150
  4c. The United Kingdom.....III-3510 $675  
   A. Market Analysis.....III-35
Outlook.....III-35
Market Overview.....III-35
Table 43: UK Market for Inhaled Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Serevent, Ventolin, Pulmicort, Flovent, Beclovent, Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other (includes corresponding Graph/Chart).....III-35
Areas of Growth .....III-35
1$150
   Progress in Drug Delivery.....III-36
Asthma Incidence among Children.....III-36
Product Launches/Developments.....III-36
1$75
   Strategic Corporate Developments.....III-374$300
   Select Players.....III-412$150
   B. Market Analytics.....III-43
Table 44: UK Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-43

Table 45: UK Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-43
1$150
   Table 46: UK 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-44
1$150
  4d. Italy.....III-454 $350  
   A. Market Analysis.....III-45
Outlook.....III-45
Competitive Landscape.....III-45
Table 47: Italian Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Major Brands- Pulmicort, Ventolin, Beclovent, Flovent, Serevent, Atrovent, Flonase, Vancenase Pocket, Vancenase, and Other (includescorresponding Graph/Chart).....III-45
1$150
   Strategic Corporate Developments.....III-46
Chiesi Farmaceutici SpA – A Major Italian Player.....III-46
1$75
   B. Market Analytics.....III-47
Table 48: Italian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart).....III-47
1$150
   Table 49: Italian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-48

Table 50: Italian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-48
1$150
  4e. Spain.....III-493 $325  
   A. Market Analysis.....III-49
Outlook.....III-49
Competitive Landscape.....III-49
Table 51: Spanish Market for Pulmonary Drug Delivery Systems (2004): Percentage Share Breakdown of Sales by Leading Brands- Pulmicort, Beclovent, Serevent, Ventolin, Atrovent, Flonase, Flovent, Vancenase Pocket, and Others (includes corresponding Graph/Chart).....III-49
1$150
   B. Market Analytics.....III-50
Table 52: Spanish Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-50

Table 53: Spanish Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-50
1$150
   Table 54: Spanish 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-51
1$150
  4f. Russia.....III-522 $175  
   Market Analysis.....III-52
Table 55: Russian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-52
1$150
   Table 56: Russian Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-53

Table 57: Russian 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-53
1$150
  4g. Rest of Europe.....III-544 $300  
   A. Market Analysis.....III-54
Outlook.....III-54
Ireland.....III-54
Growth of Systemic Drug Delivery Device Market in Chaos.....III-54
Sweden.....III-54
Prominent Position in DPIs.....III-54
The Netherlands.....III-54
1$75
   Product Launch.....III-55
Strategic Corporate Development.....III-55
1$75
   B. Market Analytics.....III-56
Table 58: Rest of Europe Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-56
1$150
   Table 59: Rest of Europe Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-57

Table 60: Rest of Europe 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-57
1$150
  5. Asia-Pacific.....III-584 $325  
   A. Market Analysis.....III-58
Outlook.....III-58
China.....III-58
Market Scenario.....III-58
India.....III-58
Market Scenario.....III-58
Dry Powder Inhalers for Children.....III-58
1$75
   Device Prices.....III-59
Australia.....III-59
Asthma: The Most Common Chronic Suffering Among Australians.....III-59
Australia Finding Preventives for Asthma Cure.....III-59
Use of CFCs in Australia.....III-59
1$75
   B. Market Analytics.....III-60
Table 61: Asia Pacific Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-60
1$150
   Table 62: Asia Pacific Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015(includes corresponding Graph/Chart).....III-61

Table 63: Asia Pacific 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008, and 2012 (includes corresponding Graph/Chart).....III-61
1$150
  6. Latin America.....III-622 $175  
   A. Market Analysis.....III-62
Outlook.....III-62
Brazil.....III-62
B. Market Analytics.....III-62
Table 64: Latin America Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-62
1$150
   Table 65: Latin America Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-63

Table 66: Latin America 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Salesfor Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003,2008 and 2012 (includes correspondingGraph/Chart).....III-63
1$150
  7. Rest of World.....III-642 $300  
   Market Analysis.....III-64
Table 67: Rest of the World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered DoseInhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-64
1$150
   Table 68: Rest of the World Long-term Projections for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-65

Table 69: Rest of the World 10-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Nebulizers Markets for 2003, 2008 and 2012 (includes corresponding Graph/Chart).....III-65
1$150
IV. COMPETITIVE LANDSCAPE 141$995
     
  
Total Companies Profiled: 55 (including Division/Subsidiaries - 64)

Region/Country                 Players

The United States                 38
Canada                             2
Japan                              3
Europe                            20 
     France                        1
     Germany                       1
     The United Kingdom           10
     Italy                         2
     Rest of Europe                6
Middle East                        1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2009, Global Industry Analysts, Inc., USA.